{"title":"伊朗西北部地区炎症性肠病患者肠道菌群和短链脂肪酸的研究","authors":"Samira Saedi, Safoura Derakhshan, Javid Sadeghi, Alka Hasani, Manouchehr Khoshbaten, Vahdat Poortahmasebi, Somayeh Ahmadi","doi":"10.1093/lambio/ovaf111","DOIUrl":null,"url":null,"abstract":"<p><p>The gut microbiota, which plays a vital role in synthesizing short-chain fatty acids (SCFAs), is involved in the pathogenesis of inflammatory bowel disease (IBD). This study aimed to evaluate four phyla of gut microbiota and main SCFAs in IBD patients compared to the control group. Stool samples from 40 IBD patients [including ulcerative colitis (UC) and Crohn's disease (CD)] and 20 healthy controls were analyzed. Quantitative polymerase chain reaction was used to assess the abundance of four major gut microbiota phyla, and SCFA concentrations were measured using high-performance liquid chromatography. Results showed that Firmicutes levels were significantly lower in both UC and CD patients compared to controls. Bacteroidetes were significantly reduced in CD patients, while proteobacteria were significantly elevated in UC patients. No significant differences were observed in Actinobacteria levels. Regarding SCFAs, butyric acid was significantly lower in both UC and CD patients. Additionally, acetic acid and propionic acid were significantly decreased only in UC patients. These findings highlight the presence of gut dysbiosis and altered SCFA profiles in IBD patients. Given the protective roles of gut microbiota and their metabolites, strategies to restore microbial balance and SCFA production may support the management and treatment of IBD.</p>","PeriodicalId":17962,"journal":{"name":"Letters in Applied Microbiology","volume":" ","pages":""},"PeriodicalIF":2.1000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A study on gut microbiota and short-chain fatty acids in patients with inflammatory bowel disease from northwest Iran.\",\"authors\":\"Samira Saedi, Safoura Derakhshan, Javid Sadeghi, Alka Hasani, Manouchehr Khoshbaten, Vahdat Poortahmasebi, Somayeh Ahmadi\",\"doi\":\"10.1093/lambio/ovaf111\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The gut microbiota, which plays a vital role in synthesizing short-chain fatty acids (SCFAs), is involved in the pathogenesis of inflammatory bowel disease (IBD). This study aimed to evaluate four phyla of gut microbiota and main SCFAs in IBD patients compared to the control group. Stool samples from 40 IBD patients [including ulcerative colitis (UC) and Crohn's disease (CD)] and 20 healthy controls were analyzed. Quantitative polymerase chain reaction was used to assess the abundance of four major gut microbiota phyla, and SCFA concentrations were measured using high-performance liquid chromatography. Results showed that Firmicutes levels were significantly lower in both UC and CD patients compared to controls. Bacteroidetes were significantly reduced in CD patients, while proteobacteria were significantly elevated in UC patients. No significant differences were observed in Actinobacteria levels. Regarding SCFAs, butyric acid was significantly lower in both UC and CD patients. Additionally, acetic acid and propionic acid were significantly decreased only in UC patients. These findings highlight the presence of gut dysbiosis and altered SCFA profiles in IBD patients. Given the protective roles of gut microbiota and their metabolites, strategies to restore microbial balance and SCFA production may support the management and treatment of IBD.</p>\",\"PeriodicalId\":17962,\"journal\":{\"name\":\"Letters in Applied Microbiology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Letters in Applied Microbiology\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1093/lambio/ovaf111\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOTECHNOLOGY & APPLIED MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Letters in Applied Microbiology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1093/lambio/ovaf111","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
A study on gut microbiota and short-chain fatty acids in patients with inflammatory bowel disease from northwest Iran.
The gut microbiota, which plays a vital role in synthesizing short-chain fatty acids (SCFAs), is involved in the pathogenesis of inflammatory bowel disease (IBD). This study aimed to evaluate four phyla of gut microbiota and main SCFAs in IBD patients compared to the control group. Stool samples from 40 IBD patients [including ulcerative colitis (UC) and Crohn's disease (CD)] and 20 healthy controls were analyzed. Quantitative polymerase chain reaction was used to assess the abundance of four major gut microbiota phyla, and SCFA concentrations were measured using high-performance liquid chromatography. Results showed that Firmicutes levels were significantly lower in both UC and CD patients compared to controls. Bacteroidetes were significantly reduced in CD patients, while proteobacteria were significantly elevated in UC patients. No significant differences were observed in Actinobacteria levels. Regarding SCFAs, butyric acid was significantly lower in both UC and CD patients. Additionally, acetic acid and propionic acid were significantly decreased only in UC patients. These findings highlight the presence of gut dysbiosis and altered SCFA profiles in IBD patients. Given the protective roles of gut microbiota and their metabolites, strategies to restore microbial balance and SCFA production may support the management and treatment of IBD.
期刊介绍:
Journal of & Letters in Applied Microbiology are two of the flagship research journals of the Society for Applied Microbiology (SfAM). For more than 75 years they have been publishing top quality research and reviews in the broad field of applied microbiology. The journals are provided to all SfAM members as well as having a global online readership totalling more than 500,000 downloads per year in more than 200 countries. Submitting authors can expect fast decision and publication times, averaging 33 days to first decision and 34 days from acceptance to online publication. There are no page charges.